Endometrial tumors with yolk sac tumor-like morphologic patterns or immunophenotypes: an expanded appraisal
| Autor: | Nada Shaker, Philip P.C. Ip, Nuha Shaker, Andres A. Roma, Lien N. Hoang, Jonathan L. Hecht, Abrar G. Alghamdi, Vinita Parkash, Raji Ganesan, Krisztina Z. Hanley, Oluwole Fadare, Hussain Abubakr |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty CD30 Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine SALL4 Carcinosarcoma Biomarkers Tumor Carcinoma medicine Humans Yolk sac biology CD117 business.industry Endodermal Sinus Tumor medicine.disease Immunohistochemistry Endometrial Neoplasms 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis embryonic structures biology.protein Female business PAX8 |
| Zdroj: | Modern Pathology. 32:1847-1860 |
| ISSN: | 0893-3952 |
| Popis: | Uterine yolk sac tumors have gained increased recognition in recent years. The current study is a multi-faceted examination of yolk sac tumor-like phenotypes in endometrial tumors, based on an analysis of 3 groups of uterine tumors: Group 1: 9 endometrial tumors that had been classified as yolk sac tumor, or as having a yolk sac tumor component, were assessed with a 35-marker immunohistochemical panel, with the goal of defining their immunophenotypic spectrum; Group 2, comprised of 70 endometrial carcinomas of various histotypes, were analyzed for their expression of SALL4, Glypican-3, and AFP, to assess the specificity of these markers for yolk sac tumors relative to endometrial carcinomas; Group 3, comprised of 626 archived cases of endometrial carcinoma/carcinosarcoma, reviewed to define the frequency of yolk sac tumor-like morphology therein. Yolk sac tumor areas in the Group 1 cases were consistently immunoreactive for SALL4 and Glypican-3; variably positive for AFP (89%), Villin (89%), PLAP (78%), 34βE12 (67%), CAM 5.2 (62.5%), EMA (56%), CD117 (50%), p16 (50%), CDX2 (44%), p53 (44% aberrant), MOC31 (37.5%), CK7 (33%), GATA3 (33%), CK5 (25%), and PAX8 (11%); and were negative for CD30, Napsin A, OCT4, estrogen, androgen, and progesterone receptors. 29 (41%) of the 70 group-2 cases expressed at least one of the 3 markers, and 96% of the positive cases was a high-grade histotype. Glypican-3, SALL4, and AFP were positive in 30, 20, and 2.8% of group-2 cases respectively; however, co-expression of any 2, or all 3 markers was uncommon ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink